Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q2 2026 Earnings Presentation
39 slides from Genedx's earnings presentation, Aug 3, 2026
Slide 1: GeneDx Q2 2026 Earnings Presentation
GeneDx Nasdaq: WGS Q2 2026 Earnings Presentation August 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market
Slide 3: Q2 2026 Results
Q2 2026 Results Metric Second Quarter 2026 Revenue $114.4 million Exome and genome volume 30,785 Exome and genome revenue $100.3 million Adjusted gross margin1 70% Adjusted net income1 $0.4 million Cash on hand $133.5 million Pro forma cash on hand2 Approximately $188 million 1 Adjusted gross margin
Slide 4: Strong demand drove exome and genome volume growth
Strong demand drove exome and genome volume growth Exome and Genome Volume 30,785 Exome and genome volume 30,000 year-over-year: 25,000 23,246 • Q2 2026 YoY: up 32% to 20,000 18,017 30,785 15,000 • Unit growth was broad- 10,000 based across geneticists, pediatric neurology, and 5,000 NICU 0 Q2 Q3 Q4
Slide 5: Revenue growth rebounded as mix shift toward genome moderated
Revenue growth rebounded as mix shift toward genome moderated Exome and Genome Revenue (in $M) $120 Exome and genome revenue $100.3 year-over year: $100 $86.0 • Q2 2026 YoY: up 17% to $80 $100.3M $60 $50.7 • Q2 ARR: ~$3,250 $40 • Primary driver of YoY ARR variability is product mix $20 shift into wh
Slide 6: We've organized the company around three key imperatives
We've organized the company around three key imperatives Optimize unit Grow utilization of Deliver the leading economics exome and genome products at unmatched scale 6
Slide 7: Focused on four operational levers to improve blended average reimbursement rates
Focused on four operational levers to improve blended average reimbursement rates Manage Mix Implement Payer-Specific 1 3 Workflows 2 Expand Payer Coverage 4 Invest In Technology 7
Slide 8: 2026 Guidance
2026 Guidance Metric Full Year 2026 Guidance Third Quarter 2026 Guidance Revenue $475 to $490 million $122 to $124 million Exome and genome volume At least 30% growth 33,200 tests Exome and genome revenue At least 20% growth $110 to $112 million Adjusted gross margin1 Approximately 70% Approximately
Slide 9: Appendix
Appendix 9 Confidential & Proprietary. Do Not Distribute.
Slide 10: Empowering everyone to live their healthiest life through genomics
Empowering everyone to live their healthiest life through genomics 10
Slide 11: GeneDx is the global leader in rare disease diagnosis
GeneDx is the global leader in rare disease diagnosis The #1 genetic test GeneDx InfinityTM Experience & Technology Preferred by 80% of geneticists The largest and most diverse Diagnosing more rare disease and granted FDA Breakthrough rare disease dataset to deliver patients than anyone else and Dev
Slide 12: An accurate genetic diagnosis is key to transforming healthcare
An accurate genetic diagnosis is key to transforming healthcare Enabling precision Providing an early Fueling genomic and accurate drug medicine genetic diagnosis discovery 12
Slide 13: Delivering the future of precision medicine via the network effect
Delivering the future of precision medicine via the network effect Patients Biopharma Delivering faster, more accurate diagnosis Accelerating drug discovery, enabling with personalized treatments based on clinical trials, and unlocking biomarkers for biology, leading to better outcomes targeted ther
Slide 14: Trusted by the nation's leading health systems
Trusted by the nation’s leading health systems 14
Slide 15: GeneDx Infinity is the largest and most diverse rare disease dataset
GeneDx InfinityTM is the largest and most diverse rare disease dataset ~1M >2.5M The most accurate exomes & genetic diagnosis genomes tests 2x the answers compared to public datasets >8M >8M Greatest scale advantage health phenotypic datapoints Fastest diagnosis and records most efficient operations
Slide 16: AI strategy accelerates the flywheel effect of our data
Higher diagnostic yields and more Additional Our AI strategy accelerates answers patients tested the flywheel effect of our data ELS OD M E M G A A U C The compounding power of the data G H IN AN from each new patient informs more E LARGE L LEA diagnoses and extends our lead RNING Proprietary AI mod
Slide 17: This large and ever-growing opportunity is ours to win
This large and ever-growing opportunity is ours to win Upside Opportunities International, Biopharma/Data, Precision Medicine Adult $20B Adult Neurologists, Adult Cardiologists, and Other Specialists Pediatrics & Rare Pediatric Specialists, Pediatricians, $25B NICU, Prenatal, and gNBS 17
Slide 18: On average, an accurate diagnosis takes 5 years
On average, an accurate diagnosis takes 5 years The economic burden of rare diseases in the U.S. is over $1 trillion annually Referral to a No diagnosis Visit primary care specialist physician Genetic testing (CMA) GeneDx provides First answers in symptom Online Another months research specialist Or
Slide 19: We are monitoring key metrics that translate to higher blended ARR over time
We are monitoring key metrics that translate to higher blended ARR over time 1 Product Mix 2 Payer Policy Coverage Commercial Covered Lives State Medicaid Policies Q2 outpatient Cover outpatient exome genome mix 90% 98% 87% 39 and/or genome 47% 37 Cover outpatient exome 3 Collection Rate Q1 Q2 Exome
Slide 20: Medicaid programs across the country are expanding access
Medicaid programs across the country are expanding access Current Medicaid Coverage Landscape Exome Coverage Only Genome Coverage Only Exome and Genome Coverage No Coverage New or Enhanced Coverage 20 1. GeneDx Internal Data, data on file 2026
Slide 21: Our north star is to diagnose as many people as fast as possible
Our north star is to diagnose as many people as fast as possible 21
Slide 22: Our stacked, compounding growth strategy unlocks new opportunities
Our stacked, compounding growth strategy unlocks new opportunities Three layers, multiple building blocks to sustained high growth with disciplined expansion plan Future • gNBS Markets • New Channels (Developing) • BioPharma & Data Expansion • General Pediatricians (H2 2026) • NICU (since 2024) Mark
Slide 23: Core markets continued to perform well while expansion markets gain momentum
Core markets of geneticists and pediatric neurologists continued to perform well while expansion markets gain momentum Clinician Penetration by Market Patient Penetration by Market 100% 100% 90% 90% 80% 80% 70% 70% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Geneticsits Geneticists Pediatr
Slide 24: Entering new markets to deliver answers at the earliest moment possible
Entering new markets to deliver answers at the earliest moment possible Standard of care: years of disease progression Prenatal NICU Pediatrician Pediatric Geneticist Adult Specialist Specialist 24
Slide 25: Geneticists remain key customers and prefer GeneDx
Foundational Market Geneticists remain key customers and prefer GeneDx Geneticist recommendations reinforce our leadership in new markets Leading position: 80% market share driven by superior accuracy, broad access, and cutting-edge discovery Continued growth: Largest contributor to revenue today wi
Slide 26: Pediatric specialists continue drive high growth
Foundational Market Pediatric specialists continue drive high growth Increased ordering and new customer activation driving expansion Significant share: Over 30% of pediatric neurologists now order from us with continued growth ahead Strong awareness: Greatest brand recognition of any genetics lab -
Slide 27: Pediatricians are becoming the new front line of genomic medicine
Expansion Pediatricians are becoming the new front line of Market genomic medicine First mover to an untapped market with the #1 genetic test in hand Massive market: 600K patients diagnosed with DD/ID by 25K pediatricians annually Trusted partner & clear leader: Leading product, wraparound services,
Slide 28: The NICU is an untapped opportunity for early intervention and improved outcomes
Expansion Market The NICU is an untapped opportunity for early intervention and improved outcomes Taking a protocol-driven approach to benefit more patients and lower healthcare costs Large unmet need: Up to 60% NICU patients could benefit from rWGS per SeqFirst (~235k patients) but less than 5% of
Slide 29: GenomeDx Prenatal extends our diagnostic capabilities into prenatal care
Expansion GenomeDx Prenatal extends our industry-leading Market diagnostic capabilities into prenatal care Setting a new standard for prenatal genomic diagnoses Large unmet need: For patients with structural anomalies on prenatal ultrasound, impacting up to 4% of pregnancies Extensive prenatal exper
Slide 30: Adult specialists will unlock future growth and impact
Expansion Market Adult specialists will unlock future growth and impact Putting commercial focus behind the organic growth in adult exome and genome testing New market: Expanding to neurologists in 2026 with a focus on clinicians already ordering genetic testing Green space: Strong demand and reimbu
Slide 31: Global reach with decentralized testing powered by GeneDx Infinity
Expansion Global reach with decentralized testing powered by Market centralized intelligence from GeneDx InfinityTM Cloud-native platform enables remote interpretation while complying with local regulations Expanded international footprint with sales reps in key geographies Providing leading interpr
Slide 32: Transforming healthcare from diagnostic odyssey to day one action with gNBS
Future Transforming healthcare from diagnostic odyssey to Market day one action with gNBS GeneDx has the evidence, experience, and operational capabilities to lead global adoption Evidence Experience Capabilities Data from the GUARDIAN study: • Sequenced >22,000 newborns • Flexible services – from e
Slide 33: Pioneering new channels and partnerships to deliver on precision genomic medicine
Future Pioneering new channels and partnerships to deliver Market on the promise of precision genomic medicine 33
Slide 34: Deploying the most comprehensive, longitudinal dataset for rare disease ever assembled
Future Deploying the most comprehensive, longitudinal Market dataset for rare disease ever assembled Genetic data Claims Electronic Prescription health records Patient Imaging demographics Unlocking faster HEOR, biopharma innovation, and AI-driven discovery 34
Slide 35: Turning insight into biopharma impact
Turning insight into biopharma impact 35
Slide 36: Proven leadership driving high-growth and operational excellence at scale
Proven leadership driving high-growth and operational excellence at scale Katherine Stueland Kevin Feeley Mark Gardner Bryan Dechairo Melanie Duquette Chief Executive Officer Chief Financial Officer President Chief Operating Officer Chief Growth Officer Lisa Gurry Heidi Chen Linda Genen Jami Biliboa
Slide 37: A rare opportunity to transform healthcare fueled by unmatched data and momentum
A rare opportunity to transform healthcare fueled by unmatched data and momentum Massive TAM and expanding Emerging guidelines and serviceable market improving payer landscape Leadership position Scale advantage Differentiated technology Proven management team 37
Slide 38: Our core competitive advantage compounds with every patient we test
Our core competitive advantage compounds with every patient we test. We are setting the industry standard, delivering actionable answers for families and sustainable value for shareholders. 38
Slide 39: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures Adjusted gross profit, adjusted gross margin, and adjusted net income (loss) (in $ thousands) Three months ended June 30, 2026 June 30, 2025 March 31, 2026 Revenue $ 114,440 $ 102,692 $ 102,254 Cost of services 36,202 31,790 34,043 Gross profit $ 78,238